Spyre Therapeutics Unveils Promising First Quarter 2025 Results with Major Corporate Updates Spyre Therapeutics shares encouraging results from Q1 2025, highlighting progress in clinical trials for IBD and RA while strengthening its financial position.

Spyre Therapeutics Unveils Promising First Quarter 2025 Results with Major Corporate Updates #USA #Spyre_Therapeutics #Waltham #IBD_Research #RA_Treatment

Spyre Therapeutics Showcases Promising Findings at ECCO 2025 on Innovative IBD Treatments Spyre Therapeutics presents pivotal research at the ECCO conference, demonstrating enhanced efficacy for IBD therapies combining two antibody targets. Find out more!

Spyre Therapeutics Showcases Promising Findings at ECCO 2025 on Innovative IBD Treatments #Germany #Berlin #Spyre_Therapeutics #IBD_Research #ECCO_2025

Mozart Therapeutics Unveils Promising New Preclinical Findings for MTX-201 at Crohn's and Colitis Congress 2025 New preclinical results presented by Mozart Therapeutics at the Crohn's and Colitis Congress highlight the potential of MTX-201 in treating IBD.

Mozart Therapeutics Unveils Promising New Preclinical Findings for MTX-201 at Crohn's and Colitis Congress 2025 #United_States #San_Francisco #Mozart_Therapeutics #MTX-201 #IBD_Research